Physician profile
Sumit Tiwari
NPI 1215048574
$7,847.50
in general payments reported to CMS, 2019-2025
36 companies · $1,948 in 2025
The $1,948 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $145 · 2020: $187 · 2021: $416 · 2022: $1,650 · 2023: $1,443 · 2024: $2,059 · 2025: $1,948.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,449.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $813.36 | 2022-2025 | |
| Amgen INC. | $751.15 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $628.89 | 2021-2024 | Xarelto |
| Pfizer INC. | $619.72 | 2022-2025 | |
| Boston Scientific Corporation | $619.37 | 2020-2025 | Watchman Access System, Rotablator Rotational Atherectomy System Console Kit, Synergy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $510.01 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $505.78 | 2021-2025 | Verquvo, Capvaxive |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $369.34 | 2021-2025 | Lifevest |
| Shockwave Medical, INC | $326.55 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| E.R. Squibb & Sons, L.L.C. | $304.79 | 2021-2024 | Eliquis, Camzyos |
| Abiomed | $262.17 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $258.04 | 2022-2025 | Brilinta, Farxiga, Wainua |
| Medtronic Vascular, INC. | $253.99 | 2019-2020 | |
| Novo Nordisk INC | $218.88 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $159.38 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $148.80 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $125.31 | 2022-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $124.30 | 2023-2024 | |
| Abbott Laboratories | $111.51 | 2021-2024 | Aveir, Jot Dx |
| Lexicon Pharmaceuticals, INC. | $109.46 | 2023-2024 | Inpefa |
| Baxter Healthcare | $96.07 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Lilly USA, LLC | $80.21 | 2022-2025 | Zepbound, Mounjaro |
| Medtronic, INC. | $65.94 | 2021-2023 | In.Pact Av, Linq II |
| Amarin Pharma, INC. | $61.45 | 2021-2022 | |
| Irhythm Technologies, INC. | $59.34 | 2024 | Zio Monitor, Zio Xt Patch |
| Esperion Therapeutics, INC. | $38.27 | 2024 | Nexletol |
| Edwards Lifesciences Corporation | $37.98 | 2022-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Scpharmaceuticals INC. | $34.04 | 2023-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $28.00 | 2023 | Arcalyst |
| Angiodynamics, INC. | $27.91 | 2022 | |
| Cvrx, INC. | $18.27 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.94 | 2023 | Opsumit |
| Philips North America LLC | $16.95 | 2024 | (Ck4) Mcot |
| Csl Behring | $16.53 | 2021 | |
| Heartflow, INC. | $13.99 | 2025 | |
| Alnylam Pharmaceuticals INC. | $13.81 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Tiwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.